Subscribe
shutterstock_1905552877_nitpicker
nitpicker / Shutterstock.com
5 April 2022EuropeMuireann Bolger

Pharma patent filings rise at EPO amid pandemic

Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office (EPO).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Compugen’s anti-PVRIG patent upheld by the EPO
18 July 2023   Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Big Pharma
Biopharma group urges fairer access to pandemic protection
21 July 2022   Global industry body launches declaration | Poorer nations could benefit from more equitable vaccine access | Proposal to be tabled among G7 and G20.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Biotechnology
Compugen’s anti-PVRIG patent upheld by the EPO
18 July 2023   Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Big Pharma
Biopharma group urges fairer access to pandemic protection
21 July 2022   Global industry body launches declaration | Poorer nations could benefit from more equitable vaccine access | Proposal to be tabled among G7 and G20.

More on this story

Biotechnology
Compugen’s anti-PVRIG patent upheld by the EPO
18 July 2023   Opposition Division ruling supports the use of immunotherapy patent | Highlights the significance of plausibility in patent evaluation following G 2/21.
Europe
EPO Enlarged Board of Appeal issues G 2/21 decision
28 March 2023   Board provides guidance on evidence submitted after patent filing date | Eagerly awaited decision confirms what’s needed to prove a certain effect.
Big Pharma
Biopharma group urges fairer access to pandemic protection
21 July 2022   Global industry body launches declaration | Poorer nations could benefit from more equitable vaccine access | Proposal to be tabled among G7 and G20.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB